Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254315750> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4254315750 endingPage "3055" @default.
- W4254315750 startingPage "3055" @default.
- W4254315750 abstract "3055 Background: Antiangiogenic therapy is a promising strategy to inhibit tumor growth and the formation of metastases. Vascular endothelial growth factor (VEGF) is a key proangiogenic factor essential for the development of new tumor blood vessels. AZD2171 is an orally available, highly potent inhibitor of VEGF receptor tyrosine kinase that has been assessed in a Phase I study of patients with advanced cancer and liver metastases. This study was designed to evaluate the safety and tolerability of ascending doses of AZD2171. Additional assessment of pharmacokinetics (PK), surrogate markers of activity and antitumor effects was also made. Methods: Cohorts of three patients received a single oral dose of AZD2171 (0.5, 1, 2.5, 5 or 10 mg p.o.) followed by a 7-day washout period and then received daily dosing at the same dose for a total of 28 days. Further 28-day treatment cycles were administered until a withdrawal criterion was met. Results: To date, 16 patients with advanced cancers and liver metastases (9 female, 7 male, median age 57 years) have been treated with AZD2171. Preliminary PK data indicate that AZD2171 is rapidly absorbed with a median time to maximal plasma concentration of 3.0 hours and a grand arithmetic mean terminal phase half-life of 20 hours. The exposure observed following continuous once-daily dosing for 28 days was entirely consistent with the terminal phase half-life obtained after a single oral dose. The PK profile appears to be linear following single and multiple doses. Treatment was well tolerated at the dose levels evaluated and the MTD has not been established. In the 10 mg cohort, one patient developed CTC grade 2 dizziness. No other drug-related toxicities have been observed. Conclusion: Continuous, once-daily, oral treatment with the highly potent VEGF receptor tyrosine kinase inhibitor, AZD2171, was well tolerated in this ongoing Phase I study. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca; ProQinase AstraZeneca" @default.
- W4254315750 created "2022-05-12" @default.
- W4254315750 creator A5000783146 @default.
- W4254315750 creator A5022888523 @default.
- W4254315750 creator A5027572658 @default.
- W4254315750 creator A5031067983 @default.
- W4254315750 creator A5037655243 @default.
- W4254315750 creator A5047860622 @default.
- W4254315750 creator A5047995423 @default.
- W4254315750 creator A5053354533 @default.
- W4254315750 creator A5062420789 @default.
- W4254315750 creator A5064684263 @default.
- W4254315750 date "2004-07-15" @default.
- W4254315750 modified "2023-09-26" @default.
- W4254315750 title "Phase I dose-escalation study of the highly potent VEGF receptor kinase inhibitor, AZD2171, in patients with advanced cancers with liver metastases" @default.
- W4254315750 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.3055" @default.
- W4254315750 hasPublicationYear "2004" @default.
- W4254315750 type Work @default.
- W4254315750 citedByCount "7" @default.
- W4254315750 crossrefType "journal-article" @default.
- W4254315750 hasAuthorship W4254315750A5000783146 @default.
- W4254315750 hasAuthorship W4254315750A5022888523 @default.
- W4254315750 hasAuthorship W4254315750A5027572658 @default.
- W4254315750 hasAuthorship W4254315750A5031067983 @default.
- W4254315750 hasAuthorship W4254315750A5037655243 @default.
- W4254315750 hasAuthorship W4254315750A5047860622 @default.
- W4254315750 hasAuthorship W4254315750A5047995423 @default.
- W4254315750 hasAuthorship W4254315750A5053354533 @default.
- W4254315750 hasAuthorship W4254315750A5062420789 @default.
- W4254315750 hasAuthorship W4254315750A5064684263 @default.
- W4254315750 hasConcept C112705442 @default.
- W4254315750 hasConcept C121608353 @default.
- W4254315750 hasConcept C126322002 @default.
- W4254315750 hasConcept C126894567 @default.
- W4254315750 hasConcept C143998085 @default.
- W4254315750 hasConcept C167734588 @default.
- W4254315750 hasConcept C197934379 @default.
- W4254315750 hasConcept C2777025900 @default.
- W4254315750 hasConcept C2777288759 @default.
- W4254315750 hasConcept C2778375690 @default.
- W4254315750 hasConcept C71924100 @default.
- W4254315750 hasConcept C90924648 @default.
- W4254315750 hasConcept C98274493 @default.
- W4254315750 hasConceptScore W4254315750C112705442 @default.
- W4254315750 hasConceptScore W4254315750C121608353 @default.
- W4254315750 hasConceptScore W4254315750C126322002 @default.
- W4254315750 hasConceptScore W4254315750C126894567 @default.
- W4254315750 hasConceptScore W4254315750C143998085 @default.
- W4254315750 hasConceptScore W4254315750C167734588 @default.
- W4254315750 hasConceptScore W4254315750C197934379 @default.
- W4254315750 hasConceptScore W4254315750C2777025900 @default.
- W4254315750 hasConceptScore W4254315750C2777288759 @default.
- W4254315750 hasConceptScore W4254315750C2778375690 @default.
- W4254315750 hasConceptScore W4254315750C71924100 @default.
- W4254315750 hasConceptScore W4254315750C90924648 @default.
- W4254315750 hasConceptScore W4254315750C98274493 @default.
- W4254315750 hasIssue "14_suppl" @default.
- W4254315750 hasLocation W42543157501 @default.
- W4254315750 hasOpenAccess W4254315750 @default.
- W4254315750 hasPrimaryLocation W42543157501 @default.
- W4254315750 hasRelatedWork W1736016875 @default.
- W4254315750 hasRelatedWork W2037651778 @default.
- W4254315750 hasRelatedWork W2064759457 @default.
- W4254315750 hasRelatedWork W2104484219 @default.
- W4254315750 hasRelatedWork W2131499894 @default.
- W4254315750 hasRelatedWork W2228940554 @default.
- W4254315750 hasRelatedWork W2890419855 @default.
- W4254315750 hasRelatedWork W2922882148 @default.
- W4254315750 hasRelatedWork W3087516196 @default.
- W4254315750 hasRelatedWork W4256521607 @default.
- W4254315750 hasVolume "22" @default.
- W4254315750 isParatext "false" @default.
- W4254315750 isRetracted "false" @default.
- W4254315750 workType "article" @default.